Published online before print June 5, 2003, doi: 10.1161/01.RES.0000080521.15238.E5
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Integrative Physiology |
Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure
From the Departments of Genomics Sciences (W.Q., J.J.G.), Cardiovascular & Metabolic Diseases (E.G.M., B.R.B., A.E.R.), Global Medical Affairs (R.R.), and Global Toxicology (E.A.G.B.), Pfizer, Inc, St Louis, Mo, and Prince Henry’s Institute of Medical Research (J.W.F.), Clayton, Victoria, Australia.
Correspondence to Ellen G. McMahon, PhD, Pfizer, Inc, 800 N Lindbergh Blvd, Mail Zone T1G, St Louis, MO 63167. E-mail ellen.g.mcmahon{at}pfizer.com
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure. Recently, both clinical and experimental studies have suggested additional, direct roles for aldosterone in the cardiovascular system. To evaluate aldosterone activation of cardiomyocyte mineralocorticoid receptors, transgenic mice overexpressing 11ß-hydroxysteroid dehydrogenase type 2 in cardiomyocytes were generated using the mouse
-myosin heavy chain promoter. This enzyme converts glucocorticoids to receptor-inactive metabolites, allowing aldosterone occupancy of cardiomyocyte mineralocorticoid receptors. Transgenic mice were normotensive but spontaneously developed cardiac hypertrophy, fibrosis, and heart failure and died prematurely on a normal salt diet. Eplerenone, a selective aldosterone blocker, ameliorated this phenotype. These studies confirm the deleterious consequences of inappropriate activation of cardiomyocyte mineralocorticoid receptors by aldosterone and reveal a tonic inhibitory role of glucocorticoids in preventing such outcomes under physiological conditions. In addition, these data support the hypothesis that aldosterone blockade may provide additional therapeutic benefit in the treatment of heart failure.
Key Words: 11ß-hydroxysteroid dehydrogenase type 2 • mineralocorticoid • eplerenone • mineralocorticoid receptor • heart failure
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure. Recently, both clinical and experimental studies have suggested additional, direct roles for aldosterone in the cardiovascular system. Plasma aldosterone concentrations correlate with left ventricular (LV) hypertrophy,1 vascular stiffness,2 heart failure, and mortality.3 In experimental hypertension, aldosterone produces blood pressure elevation by stimulating brain mineralocorticoid receptors (MRs)4 and, when combined with high salt intake, produces cardiac hypertrophy, fibrosis, and vascular inflammatory injury5–7 independent of blood pressure elevation.8 Moreover, when the new selective aldosterone blocker eplerenone was added to optimal medical therapy in a recently completed clinical study, morbidity and mortality were reduced in patients with acute myocardial infarction complicated by LV dysfunction and heart failure.9 The nonselective aldosterone blocker spironolactone produces striking improvements in morbidity and mortality in patients with severe heart failure.10
In various epithelial cells11,12 and vascular smooth muscle cells (VSMCs),13 expression of 11ß-hydroxysteroid dehydrogenase type 2 (11ß-HSD2) converts endogenous glucocorticoids to their receptor-inactive 11-keto analogues, thereby conferring aldosterone selectivity on MR. Both cardiomyocytes14,15 and VSMCs15 express MRs with equivalent, high affinities for aldosterone, corticosterone, and cortisol.16,17 However, cardiac expression of 11ß-HSD2 is extremely low,14 such that cardiomyocyte MRs are primarily occupied by endogenous glucocorticoids that are present at higher levels than aldosterone in the blood under normal conditions.
A second difference between epithelial (and VSMC) and nonepithelial MRs is their response to occupancy by endogenous glucocorticoids (cortisol in human, corticosterone in rodent). In epithelia, glucocorticoids mimic aldosterone,18 as in the syndrome of apparent mineralocorticoid excess.19–21 In nonepithelial tissues such as cardiomyocytes, glucocorticoids do not activate MR but act as antagonists.22–25 Although the mechanism underlying this difference is unknown, it may reflect tissue-specific differences in coactivator/corepressor recruitment by MR/glucocorticoid complexes, as seen with estrogen receptors.26
To examine the direct role of aldosterone in cardiac pathophysiology, we exploited the enzymatic activity of 11ß-HSD2 and generated transgenic mice that overexpressed this enzyme in cardiomyocytes, thus reducing myocardial intracellular glucocorticoids and allowing aldosterone occupancy of cardiomyocyte MR. In another study, this approach has been used to successfully inactivate natural glucocorticoids in osteoblasts in cell culture.27
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Transgenic Mice
Mouse 11ß-HSD2 cDNA was isolated by reverse transcriptase-polymerase chain reaction (RT-PCR) from mouse kidney total RNA and cloned into the plasmid Clone 26 provided by Jeffrey Robbins (University of Cincinnati, Cincinnati, Ohio) to recruit the 5.4-kb mouse
-myosin heavy chain (-MHC) promoter. The transgenic construct was released from the prokaryotic backbone and injected into the pronucleus of C57BL/6 embryos at the one-cell stage (Charles River Laboratories, Wilmington, Mass). Transgenic mice were maintained by sibling mating and used as hemizygotes. Mice received rodent chow containing 0.32% Na+ and 0.83% K+ (No. 7012, Harland Teklad), and eplerenone was administered by chow supplemented with eplerenone at 2 mg/g (Research Diets). The daily dose was 
200 mg/kg. All experimental procedures were approved by the Institutional Laboratory Animal Care and Use Committee of Pfizer, Inc.
Real-Time RT-PCR Analysis
Reagents, software, and equipment were purchased from Applied Biosystem. Taqman reactions were performed using one-step RT-PCR Master Mix Reagents with the ABI PRISM 7700 Sequence Detection System and analyzed using the Sequence Detection System software. Gene expression was normalized to cyclophilin. Primers and probes were based on GenBank sequences (11ß-HSD2, NM_008289; -MHC, M76601; ß-MHC, L07306; atrial natriuretic peptide [ANP], K02781; collagen I, U08020; collagen III, X52046; osteopontin, X14882; aldosterone synthase, S85260; matrix metalloproteinase-9 [MMP-9], NM_013599; early growth response-1 [EGR-1], NM_007913; and cyclophilin, M19533).
11ß-HSD2 Enzyme Assay
Tissue homogenates were incubated for 1 hour at 37°C in 50 µL containing 20 nmol/L [1,2,6,7-3H] corticosterone (Amersham Pharmacia Biotech, 70 Ci/mmol), 1% ethanol, 0.2% BSA, and 1 mmol/L NAD (Sigma). Steroids were extracted with ethyl acetate and resolved by thin-layer chromatography with chloroform:95% ethanol (92:8). [3H]-11-dehydrocorticosterone was identified under UV with unlabeled carrier and quantitated by scintillography. Specific activity was calculated after subtraction of background turnover.
In Situ Hybridization
Complementary RNA (cRNA) probes were generated using in vitro transcription from a 414-bp cDNA template from the mouse 11ß-HSD2 (GenBank accession No. NM_008289.1) and labeled with 33P-UTP (NEN Life Science Products). Sections were processed by standard histological techniques and hybridized overnight at 55°C in buffer (50% formamide, 2xSSC, 10% dextran sulfate) containing tRNA (50 µg/mL) and cRNA probe. Signal was detected by coating slides with NTB-2 autoradiographic emulsion (Eastman Kodak) and exposing the slides at 4°C for 1 to 2 weeks before development. Counterstaining was with H&E.
Immunohistochemistry
A primary polyclonal antibody was generated in rabbit against the peptide AAQPRSRYYPGRGLGLC from A331 to L346 of the mouse 11ß-HSD2 (NP_032315.1) and provided by Zygmunt Krozowski (Baker Heart Research Institute, Melbourne, Australia). A biotinylated anti-rabbit IgG was used as the secondary antibody. Sections were incubated with streptavidin horseradish-peroxidase (Vector Laboratories) and visualized by DAB chromogen (Vector). Counterstaining was with hematoxylin.
Collagen Content
Sections were stained with Picrosirius Red (Sigma Aldrich), and a spot RT color digital camera was used to capture 18 to 20 fields from the left ventricle of the heart sample. The images were then analyzed using Optimus v6.51 image analysis software, and the percentage of tissue that is collagen was determined.
Plasma Electrolytes and Brain Natriuretic Peptide
Plasma Na+ and K+ concentrations were determined by flame photometry (Instrumentation Laboratory), and plasma brain natriuretic peptide (BNP) concentrations were measured using the Luminex system (Luminex Corp) with a rabbit anti-rat BNP45 (Peninsula Laboratories, San Carlos, Calif).
Systolic Blood Pressure
Mice were trained for 6 days, and measurements were obtained over the next 6 days using a Visitech tail cuff system (Visitech Systems). For data collection, mice were placed on a heated platform (100°F) in a restrainer. A minimum of five preliminary cycles was performed before collecting 10 measurements for each mouse.
Echocardiography
Mice were lightly anesthetized with 1% to 2% isoflurane. Echocardiographic images were generated using a Sonos 5500 echocardiographic system with a 15-MHz linear-array transducer (Agilent). Two-dimensional parasternal long- and short-axis images of left ventricle were obtained, and 2D, targeted M-mode tracings from the parasternal short-axis view at the level of the papillary muscles were recorded (sweep speed of 150 mm/s). LV area at systole (LVAS) and LV area at diastole (LVAD) were measured directly, and LV end systolic volume (ESV) and end diastolic volume (EDV) were calculated via the method of discs from areas. Fractional shortening (FS) was calculated from the following equation: (LVIDd-LVIDs)/LVIDdx100, where LVIDd and LVIDs are end diastolic and end systolic LV internal dimensions; and ejection fraction (EF) was calculated from the following equation: (EDV-ESV)/EDVx100. All measurements were collected by the leading-edge method as recommended by the American Society for Echocardiography.
Statistical Analysis
Treatment group means were compared using one-way ANOVA of the raw data and by the least-significant differences method, with the pooled within-group mean square error as the common estimate of the variance for all mean comparisons. Estimates of variance by one-way ANOVA were obtained, and two-sided comparisons for all analyses were used.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Transgenic Mice Overexpressing 11ß-HSD2 in Cardiomyocytes Developed Cardiac Hypertrophy, Fibrosis, and Heart Failure
A mouse line that carries the transgene containing the 5.4-kb mouse
-MHC promoter28 placed 5' to the mouse 11ß-HSD2 cDNA in C57BL/6 background was created, and seven independent founder lines were obtained (Figure 1A). Based on real-time RT-PCR analysis, these founder lines had different copy numbers of the transgene (line 323, 45 copies; line 324, 2; line 325, 15; line 326, 29; line 327, 1; line 328, 4; and line 490, 27). Founder 490 died at 4.5 months of age of heart failure. At the time of death, she had a heart weight/body weight ratio of 17.5 mg/g, compared with that of 6.4 mg/g of a sex-matched, nontransgenic (non-TG) littermate. Founder 323 died at 3 months of age and was not analyzed. Founder 324 was infertile and not analyzed. At 5 months of age, cardiac 11ß-HSD2 expression increased 10 000-fold in line 325 compared with age- and sex-matched non-TG littermates, 6600-fold in line 326, 1800-fold in line 327, and 2100-fold in line 328. Importantly, in line 325, LV collagen content (% collagen volume fraction [%CVF] increased 3-fold over non-TG littermates (0.49±0.06%, non-TG, n=2, versus 1.51±0.0%, TG, n=2). Similarly, in line 327, ventricular weight/body weight ratio was increased (4.29±0.08 mg/g, non-TG, n=9, versus 5.05±0.41 mg/g, TG, n=7), as was %CVF of the LV compared with non-TG controls (0.47±0.03%, non-TG, n=8, versus 0.86±0.1%, TG, n=9). In line 326, a 10-fold increase in LV %CVF was observed (0.53±0.22%, non-TG, n=2, versus 5.3±1.25%, TG, n=3). Similar to founder 490, line 326 mice died between 4 and 6 months of age of heart failure and were used in this study.
|
The 11ß-HSD2 Gene Was Selectively Upregulated in Cardiomyocytes
In line 326 mice, the highest levels of 11ß-HSD2 induction were seen in the heart (Figure 1B), with low-level induction observed in lung, liver, spleen, brain, and skeletal muscle and no induction in kidney and colon (Figure 1C). In a previous study,28 the -MHC promoter directed gene expression to the striated muscle layer (pulmonary myocardium) of the vein in the lung and may be the cell source for induced 11ß-HSD2 expression in the lung. Although mRNA levels of 11ß-HSD2 were elevated three to four orders of magnitude in hearts from TG mice compared with hearts from non-TG mice, mRNA levels in TG hearts were 197-fold higher compared with levels in whole kidney from TG or non-TG mice. However, 11ß-HSD2 enzyme activity in hearts from TG mice was increased 70-fold in TG hearts compared with activity in hearts from non-TG mice, with no increased activity in kidney from TG mice (Figure 1D). Given that 11ß-HSD2 is expressed in 
5% of total kidney cells (Figures 2A through 2D), whereas the transgene is expressed in essentially all cardiomyocytes (Figures 2F, 2H, and 2J), 11ß-HSD2 activity per cardiomyocyte approaches that in a physiological aldosterone target tissue, the principle cells of the distal nephron.
|
In renal cortex, 11ß-HSD2 mRNA (Figures 2A and 2B) and protein (Figures 2C and 2D) were detected in epithelium of distal tubules and collecting ducts. The pattern and apparent level of 11ß-HSD2 expression was similar between non-TG (Figures 2A and 2C) and TG mice (Figures 2B and 2D), consistent with the absence of transgene expression in kidney. In transgenic hearts, expression was seen in most ventricular and atrial (not shown) cardiomyocytes at both the mRNA (Figures 2F and 2H) and protein level (Figure 2J). Notably, in non-TG hearts, 11ß-HSD2 seems to be expressed constitutively at negligible levels (Figures 2E, 2G, and 2I).
Line 326 Mice Died Prematurely at 4 to 6 Months of Age of Heart Failure
Mice from line 326 developed progressive heart failure characterized by marked dilated cardiac hypertrophy and premature death at 4 to 6 months of age (compare Figure 3B with 3A). On postmortem examination, clinical signs of heart failure were evident, such as the presence of pleural effusions and significant cardiac enlargement. All four chambers were markedly enlarged, with the heart occupying nearly the entire chest cavity. On histological examination, significant cardiomyocyte hypertrophy was evident and accompanied by extensive interstitial fibrosis (Figure 3D). Interestingly, coronary arteries did not show either endothelial or medial injury or evidence of perivascular fibrosis, suggesting that cardiomyocytes are selectively affected in this model (compare Figure 3D with 3C). This phenotype contrasts strikingly with the marked vascular inflammation and vascular remodeling associated with cardiomyocyte injury in rats when aldosterone was administered with high salt intake.7
|
Cardiac Structural and Functional Changes in Line 326 Mice
Mice at 3.5 months of age were examined extensively (Table). Systolic blood pressure (SBP) was unchanged in TG mice compared with non-TG mice under control conditions. The heart weight to body weight ratio (HW/BW) was increased more than 2-fold in TG mice compared with non-TG mice. Echocardiographic evaluation revealed a dramatic increase in LV area both at systole (LVAS) and diastole (LVAD). Even greater increases were observed in LV volume at systole and diastole. Cardiac function was also severely compromised, as evidenced by decreased fractional shortening (FS) and reduced ejection fraction (EF).
|
The Selective Aldosterone Blocker Eplerenone Significantly Attenuated the Structural and Functional Changes in 11ß-HSD2 Transgenic Mice
Under physiological conditions, cardiac MRs are overwhelmingly occupied by corticosterone. It was reasoned that by converting corticosterone into 11-dehydrocorticosterone, cardiomyocyte-specific overexpression of 11ß-HSD2 would permit aldosterone to activate cardiomyocyte MR, leading to heart failure. To test this hypothesis, we randomized non-TG and line 326 TG mice to receive either regular chow or chow supplemented with the selective aldosterone blocker eplerenone29 from 1 month to 3.5 months of age (200 mg/kg per d).
Eplerenone in non-TG mice did not significantly alter SBP or cardiac structure or function (Table). In TG mice, eplerenone also did not affect SBP but attenuated the development of cardiac hypertrophy as indicated by a reduced HW/BW ratio (Table). Systolic and diastolic LV areas and ESV and EDV were all significantly reduced by eplerenone (Table). Significantly improved indices of cardiac function, such as EF and FS, were also noted. Among all parameters, improvement in ESV and EDV were most striking such that TG eplerenone values were not statistically different from non-TG controls (Table).
Plasma sodium concentration did not differ between genotypes or treatments (Table). In contrast, there was a rise in plasma potassium concentration with eplerenone administration in TG mice, which was not observed in non-TG mice receiving eplerenone (Table). Although this presumed increased renal sensitivity to eplerenone might reflect the phenotype in TG mice, the underlying neurohormonal mechanism remains unclear. In particular, it did not seem to be attributable to differences in plasma BNP levels, which were indistinguishable among the four groups.
Eplerenone Improved Hypertrophy and Heart Failure–Associated Genes in 11ß-HSD2 Transgenic Mice
Using real-time RT-PCR, we analyzed gene expression in line 326 mice (Figure 4, compare TG to non-TG controls) and found that marker genes of mechanical overload, including ß-MHC and ANP, were elevated, whereas -MHC was downregulated. Consistent with cardiac fibrosis, expression of collagen types I and III was increased. In addition, expression of the proinflammatory cytokine osteopontin was increased. Interestingly, MMP-9 was downregulated compared with non-TG controls, whereas changes in aldosterone synthase and EGR-1 were similar in TG control and non-TG control mice.
|
Consistent with a role of aldosterone in this heart failure model, eplerenone improved the expression profile of genes associated with mechanical overload and heart failure in TG mice (Figure 4, compare TG eplerenone with TG control). Expression of the -MHC gene was elevated whereas the expression of osteopontin and collagen III were reduced with eplerenone treatment. Changes in ß-MHC, ANP, and collagen type I expression were not statistically significant. Aldosterone synthase (CYP11B2) levels were elevated in TG myocardium by eplerenone, perhaps reflecting the increase in plasma potassium in these mice. Although expression of endogenous 11ß-HSD2 was not altered by eplerenone in non-TG mice, cardiac 11ß-HSD2 expression was increased in TG mice. This response is consistent with the elevated -MHC promoter activity in TG mice treated with eplerenone.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cardiomyocyte MRs are normally occupied by endogenous glucocorticoids under physiological conditions. However, in pathophysiological states, it has been hypothesized that mineralocorticoids can access cardiac MR and produce cardiac damage. The current 11ß-HSD2 overexpression and aldosterone blockade study supports this hypothesis and is consistent with previous in vitro and in vivo studies in rat models.22–25 The demonstration that eplerenone can ameliorate the effects of 11ß-HSD2 overexpression is evidence for a specific effect via MR rather than a nonspecific effect on cardiomyocyte metabolic state, as may be the case in other studies.30,31 It remains to be understood how the 11ß-HSD2 expression correlates with cardiac hypertrophy and failure in a clinical setting, although its association with human hypertension is well documented. For example, mutations in the 11ß-HSD2 gene lead to apparent mineralocorticoid excess syndrome.19–21 In addition, the number of CA repeats located in intron 1 of the human 11ß-HSD2 gene is correlated with salt-sensitive human hypertension.32
In the present study, the myocardial vasculature was histologically unaffected by cardiomyocyte overexpression of 11ß-HSD2, with the detrimental effect confined to the cardiomyocytes. These findings are in striking contrast to studies using mineralocorticoid/salt administration in rats, where the salient response is that of vascular inflammation and vascular remodeling in the heart, associated with macrophage infiltration of the vascular and interstitial compartments and the expression of a range of proinflammatory cytokines.8 This phenotype disparity may result from limiting genetic manipulation in our study to cardiomyocytes, without involvement of the coronary vasculature. Alternatively, this difference may result from the apparent need for elevated dietary sodium intake to manifest aldosterone-driven vascular damage.33
The distinction between the cardiomyocyte response in the current study and in experiments involving mineralocorticoid/salt excess suggests separate cardiovascular roles for cardiomyocyte and VSMC MR. VSMCs express 11ß-HSD213 and thus potentially represent an aldosterone target tissue like the renal epithelial cell, where MRs are aldosterone-selective as a consequence of high levels of 11ß-HSD2 expression. This concept is additionally supported by previous studies where administration of the 11ß-HSD2 inhibitor carbenoxolone to rats induced coronary vascular inflammation that could be blocked by eplerenone, reflecting glucocorticoid activation of the otherwise inaccessible VSMC MRs.34
In contrast, in the cardiomyocyte, 11ß-HSD2 is not normally expressed, and thus MRs are unprotected. Importantly, in such nonepithelial cells, glucocorticoids act as antagonists rather than agonists of MR.22,23 In the cardiomyocyte, overexpression of 11ß-HSD2 produces pathophysiology, reflecting inappropriate occupancy and activation of MR by circumventing the presumed tonic inhibitory (or physiological antagonist) role of glucocorticoids in unprotected MRs under physiological conditions. An alternative explanation is that the pathology we observed in this model from depletion of cardiac glucocorticoids by overexpression of 11ß-HSD2 reflects a reduction in glucocorticoid receptor (GR) occupancy by corticosterone rather than MR occupancy by aldosterone. However, this interpretation is not supported by previous studies using the GR antagonist RU486, where a cardiac phenotype was not observed.23
Corticosteroids are reported to provide acute cardiovascular protection by nontranscriptional activation of endothelial nitric oxide synthase.35 Consistent with this notion, the present study suggests that corticosteroids may exert a tonic inhibitory role, preventing MR from being activated by aldosterone. However, this may be a minimalist interpretation of the data, given the evolutionary persistence of unprotected MR in the heart. Because such MRs are unprotected, they normally will be occupied by glucocorticoids, given that the levels of free glucocorticoids are 
100 times higher than those of aldosterone and that diurnal variation in cortisol and aldosterone tracks in parallel. The affinity of MR for cortisol and corticosterone is one to two orders of magnitude higher than of GR. Unprotected MRs are thus always substantially (90%) occupied by glucocorticoids, even at nadir levels.36
When 11ß-HSD2 is operating normally, it cannot sufficiently convert cortisol to cortisone to exclude it from renal MR. In the rat, in vivo direct binding studies have demonstrated that most kidney MRs under normal conditions are occupied by glucocorticoids, but these MR-glucocorticoid complexes are not transcriptionally active.37 However, when the enzyme is absent or blocked by carbenoxolone or glycyrrhetinic acid, glucocorticoid-occupied renal MRs become transcriptionally active. One possible explanation for this phenomenon lies in the fact that the operation of 11ß-HSD2 involves not only the conversion of cortisol to cortisone but of the cosubstrate NAD+ to NADH. Thus, if MR-glucocorticoid complexes are inactive under conditions of high intracellular NADH, as is the case when 11ß-HSD2 is operant, but are active when the equilibrium swings toward NAD+, then the dilemma noted above may be resolved. Redox-dependent glucocorticoid receptor–mediated responses to dexamethasone have been previously described.38,39 Such a possibility for MR may also point the way to a physiological role for MR-glucocorticoid complexes in the cardiomyocyte, that of acting as always-occupied intracellular redox sensors, as seen with the GRs.
The present study provides compelling evidence that aldosterone activation of cardiomyocyte MR leads to myocardial injury and ultimately heart failure. In congestive heart failure, plasma aldosterone levels are often elevated and correlate with mortality.3 In a comparison study in which patients with primary aldosteronism and essential hypertension were matched for severity and duration of hypertension, a higher incidence and more severe LV hypertrophy and remodeling was demonstrated in patients with primary aldosteronism.40 Even in patients with moderate essential hypertension, circulating aldosterone levels correlate with LV mass index and mean plasma levels are only slightly increased over normal.1 In addition, some reports suggest that local aldosterone production may be increased in rat heart after myocardial infarction,41 in the failing human heart,42 and in hearts from hypertensive patients without LV systolic dysfunction,43 although possible pathophysiological roles for cardiac aldosterone synthesis remain to be established. Although the deleterious consequences of aldosterone activation of cardiomyocyte MR are clearly evident, we do not yet understand how activation of MR produces cardiac injury.
|
Acknowledgments |
|---|
This work was supported by Pfizer Global R&D. We acknowledge Dr Arnold Strauss for his critical review of the manuscript. We would also like to thank Dr Zygmunt Krozowski (Baker Heart Research Institute, Melbourne, Australia) for the 11ß-HSD2 antibody, Michelle Noll (pronuclear injection), Carmen Thielemier (colony management), Ryan Philip and Mei Han (genotyping), Denise Nachowiak (Taqman), Jonathan Heyen (echocardiography), Sarbani Ghosh (blood pressure), Heather Daust (enzyme activity), Dean McGraw (blood chemistry), John Chen (plasma analysis), Gregory Frierdich, Kimberly Shevlin, and Kristen Nikula (histology), and James Kiefer (art work) for their excellent technical assistance.
|
Footnotes |
|---|
Original received February 4, 2003; revision received May 27, 2003; accepted May 28, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1996; 71: 17A–20A.
2. Duprez DA, De Buyzere ML, De Backer T, Kaufman JM, Van Hoecke MJ, Vermeulen A, Clement DL. Influence of systemic arterial blood pressure and nonhemodynamic factors on the brachial artery pulsatility index in mild to moderate essential hypertension. Am J Cardiol. 1993; 71: 350–353.[CrossRef][Medline] [Order article via Infotrieve]
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990; 82: 1730–1736.
4. Gomez-Sanchez EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology. 1986; 118: 819–823.
5. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992; 120: 893–901.[Medline] [Order article via Infotrieve]
6. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997; 35: 138–147.
7. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002; 283: H1802–H1810.
8. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1996; 269: E657–E662.
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309–1321.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709–717.
11. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 ß-hydroxysteroid dehydrogenase–tissue specific protector of the mineralocorticoid receptor. Lancet. 1988; 2: 986–989.[CrossRef][Medline] [Order article via Infotrieve]
12. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988; 242: 583–585.
13. Smith RE, Little PJ, Maguire JA, Stein-Oakley AN, Krozowski ZS. Vascular localization of the 11 ß-hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol. 1996; 23: 549–551.[Medline] [Order article via Infotrieve]
14. Sheppard KE, Autelitano DJ. 11ß-Hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology. 2002; 143: 198–204.
15. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res. 1992; 71: 503–510.
16. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987; 237: 268–275.
17. Pearce PT, Funder JW. Steroid binding to cardiac type I receptors: in vivo studies. J Hypertens Suppl. 1988; 6: S131–S133.[Medline] [Order article via Infotrieve]
18. Funder JW, Pearce PT, Myles K, Roy LP. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action. FASEB J. 1990; 4: 3234–3238.[Abstract]
19. Mune T, Rogerson FM, Nikkila A, Agarwarl AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11ß-hydroxysteroid dehydrogenase. Nat Genet. 1995; 10: 394–399.[CrossRef][Medline] [Order article via Infotrieve]
20. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE. Several homozygous mutations in the gene for 11ß-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995; 80: 3145–3150.[Abstract]
21. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11ß-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996; 347: 88–91.[CrossRef][Medline] [Order article via Infotrieve]
22. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol. 1990; 258: E649–E653.[Medline] [Order article via Infotrieve]
23. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996; 137: 4145–4153.[Abstract]
24. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994; 93: 2578–2583.[Medline] [Order article via Infotrieve]
25. Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 1996; 271: E883–E888.[Medline] [Order article via Infotrieve]
26. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002; 295: 2465–2468.
27. Woitge H, Harrison J, Ivkosic A, Krozowski Z, Kream B. Cloning and in vitro characterization of 1(I)-collagen 11ß-hydroxysteroid dehydrogenase type 2 transgenes as models for osteoblast-selective inactivation of natural glucocorticoids. Endocrinology. 2001; 142: 1341–1348.
28. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the -myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991; 266: 24613–24630.
29. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol. 2001; 1: 190–196.[CrossRef][Medline] [Order article via Infotrieve]
30. Huang WY, Aramburu J, Douglas PS, Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med. 2000; 6: 482–483.[CrossRef][Medline] [Order article via Infotrieve]
31. Beggah AT, Escoubet B, Puttini S, Cailmail S, Delage V, Ouvrard-Pascaud A, Bocchi B, Peuchmaur M, Delcayre C, Farman N, Jaisser F. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci U S A. 2002; 99: 7160–7165.
32. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, McTernan C, Bianchi G, Manunta P, Strazzullo P, Mantero F, White PC, Stewart PM. CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension. 2000; 36: 187–194.
33. Martinez DV, Rocha R, Matsumua M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 2002; 39: 614–618.
34. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11ß-hydroxysteroid dehydrogenase inactivation. Endocrinology. 2003; 144: 1121–1125.
35. Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002; 8: 473–479.[CrossRef][Medline] [Order article via Infotrieve]
36. Myles K, Funder JW. Type I (mineralocorticoid) receptors in the guinea pig. Am J Physiol. 1994; 267: E268–E272.[Medline] [Order article via Infotrieve]
37. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 1996; 137: 5264–5268.[Abstract]
38. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem. 1999; 274: 3182–3188.
39. Okamoto K, Tanaka H, Ogawa H. Makino Y, Eguchi H, Hayashi S, Yoshikawa N, Poellinger L, Umesono K, Makino I. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem. 1999; 274: 10363–10371.
40. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996; 27: 1039–1045.
41. Silvestre J-S, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999; 99: 2694–2701.
42. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001; 103: 72–77.
43. Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, Harada E, Nakamura S, Ito T, Ogawa H. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension. 2002; 39: 958–962.
This article has been cited by other articles:
 |
|
 |
|
  D. S. De Silva, R. M. Wilson, C. Hutchinson, P. C. Ip, A. G. Garcia, S. Lancel, M. Ito, D. R. Pimentel, and F. Sam Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1983 - H1993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis Eur. Heart J., January 9, 2009; (2009) ehn538v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lopez-Andres, C. Inigo, I. Gallego, J. Diez, and M. A. Fortuno Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes Endocrinology, October 1, 2008; 149(10): 4970 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Rossier, S. Lenglet, L. Vetterli, M. Python, and A. Maturana Corticosteroids and Redox Potential Modulate Spontaneous Contractions in Isolated Rat Ventricular Cardiomyocytes Hypertension, October 1, 2008; 52(4): 721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Diez Effects of Aldosterone on the Heart: Beyond Systemic Hemodynamics? Hypertension, September 1, 2008; 52(3): 462 - 464. [Full Text] [PDF]
|
|
|
|
|
|
L. Michea, A. Villagran, A. Urzua, S. Kuntsmann, P. Venegas, L. Carrasco, M. Gonzalez, and E. T. Marusic Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats Hypertension, August 1, 2008; 52(2): 295 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Molnar, C. Lindschau, G. Dubrovska, P. R. Mertens, T. Kirsch, M. Quinkler, M. Gollasch, S. Wresche, F. C. Luft, D. N. Muller, et al. Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells Hypertension, May 1, 2008; 51(5): 1372 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Endoh Novel signalling cascade for cardiac hypertrophy activation by uncoupling and internalization of {beta}1-adrenoceptors Cardiovasc Res, April 1, 2008; 78(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Rickard, J. W. Funder, J. Morgan, P. J. Fuller, and M. J. Young Does Glucocorticoid Receptor Blockade Exacerbate Tissue Damage after Mineralocorticoid/Salt Administration? Endocrinology, October 1, 2007; 148(10): 4829 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stas, A. Whaley-Connell, J. Habibi, L. Appesh, M. R. Hayden, P. R. Karuparthi, M. Qazi, E. M. Morris, S. A. Cooper, C. D. Link, et al. Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling Endocrinology, August 1, 2007; 148(8): 3773 - 3780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hsueh, E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, et al. Recipes for Creating Animal Models of Diabetic Cardiovascular Disease Circ. Res., May 25, 2007; 100(10): 1415 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fejes-Toth and A. Naray-Fejes-Toth Early Aldosterone-Regulated Genes in Cardiomyocytes: Clues to Cardiac Remodeling? Endocrinology, April 1, 2007; 148(4): 1502 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Naray-Fejes-Toth and G. Fejes-Toth Novel mouse strain with Cre recombinase in 11beta-hydroxysteroid dehydrogenase-2-expressing cells Am J Physiol Renal Physiol, January 1, 2007; 292(1): F486 - F494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Beygui, J.-P. Collet, J.-J. Benoliel, N. Vignolles, R. Dumaine, O. Barthelemy, and G. Montalescot High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction Circulation, December 12, 2006; 114(24): 2604 - 2610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Funder Aldosterone and the Cardiovascular System: Genomic and Nongenomic Effects Endocrinology, December 1, 2006; 147(12): 5564 - 5567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Reini, C. E. Wood, E. Jensen, and M. Keller-Wood Increased maternal cortisol in late-gestation ewes decreases fetal cardiac expression of 11beta-HSD2 mRNA and the ratio of AT1 to AT2 receptor mRNA Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1708 - R1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Funder Aldosterone and Mineralocorticoid Receptors: Lessons From Gene Deletion Studies Hypertension, December 1, 2006; 48(6): 1018 - 1019. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hu and J. W. Funder The Evolution of Mineralocorticoid Receptors Mol. Endocrinol., July 1, 2006; 20(7): 1471 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Turchin, C. Z. Guo, G. K. Adler, V. Ricchiuti, I. S. Kohane, and G. H. Williams Effect of Acute Aldosterone Administration on Gene Expression Profile in the Heart Endocrinology, July 1, 2006; 147(7): 3183 - 3189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lister, D. J. Autelitano, A. Jenkins, R. D. Hannan, and K. E. Sheppard Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1 Cardiovasc Res, June 1, 2006; 70(3): 555 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagata, K. Obata, J. Xu, S. Ichihara, A. Noda, H. Kimata, T. Kato, H. Izawa, T. Murohara, and M. Yokota Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats Hypertension, April 1, 2006; 47(4): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Fuller and M. J. Young Mechanisms of Mineralocorticoid Action Hypertension, December 1, 2005; 46(6): 1227 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Perrier, S. Richard, Y. Sainte-Marie, B. C. Rossier, F. Jaisser, E. Hummler, and J.-P. Benitah A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice J. Physiol., November 15, 2005; 569(1): 153 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Funder Relative Aldosterone Excess: Relative to What? Hypertension, October 1, 2005; 46(4): 643 - 644. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Funder Aldosterone, Normotension, and Diastolic Dysfunction J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5500 - 5501. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Paterson, J. R. Seckl, and J. J. Mullins Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R642 - R652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M C Connell and E. Davies The new biology of aldosterone J. Endocrinol., July 1, 2005; 186(1): 1 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ouvrard-Pascaud, Y. Sainte-Marie, J.-P. Benitah, R. Perrier, C. Soukaseum, A. N. D. Cat, A. Royer, K. Le Quang, F. Charpentier, S. Demolombe, et al. Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias Circulation, June 14, 2005; 111(23): 3025 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Katada, T. Meguro, H. Saito, A. Ohashi, T. Anzai, S. Ogawa, and T. Yoshikawa Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor-Knockout Mice After Myocardial Infarction Circulation, May 3, 2005; 111(17): 2157 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Funder The Nongenomic Actions of Aldosterone Endocr. Rev., May 1, 2005; 26(3): 313 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G.A. Veliotes, A. J. Woodiwiss, D. A.J. Deftereos, D. Gray, O. Osadchii, and G. R. Norton Aldosterone Receptor Blockade Prevents the Transition to Cardiac Pump Dysfunction Induced by {beta}-Adrenoreceptor Activation Hypertension, May 1, 2005; 45(5): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Kuster, E. Kotlyar, M. K. Rude, D. A. Siwik, R. Liao, W. S. Colucci, and F. Sam Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload Circulation, February 1, 2005; 111(4): 420 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Young and J. W. Funder Eplerenone, But Not Steroid Withdrawal, Reverses Cardiac Fibrosis in Deoxycorticosterone/ Salt-Treated Rats Endocrinology, July 1, 2004; 145(7): 3153 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, S. Clement, G. Gabbiani, J.-D. Horisberger, M. Burnier, B. C. Rossier, and E. Hummler Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1178 - F1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsui, N. Jia, H. Okamoto, S. Kon, H. Onozuka, M. Akino, L. Liu, J. Morimoto, S. R. Rittling, D. Denhardt, et al. Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II-Induced Cardiac Hypertrophy Hypertension, June 1, 2004; 43(6): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tsybouleva, L. Zhang, S. Chen, R. Patel, S. Lutucuta, S. Nemoto, G. DeFreitas, M. Entman, B. A. Carabello, R. Roberts, et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy Circulation, March 16, 2004; 109(10): 1284 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||